nach oben

Journal of Neurology

Erschienen in:

30.01.2020 | Neurological Update

The neurological update: therapies for cerebellar ataxias in 2020

verfasst von: J. Gandini, Mario Manto, T. Bremova-Ertl, K. Feil, M. Strupp

Erschienen in: Journal of Neurology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Cerebellar ataxias (CAs) represent a heterogeneous group of sporadic or inherited disorders. The clinical spectrum of CAs is continuously expanding. Our understanding of the mechanisms leading to the clinical deficits has improved over these last decades, in particular thanks to progress in genetics, neuroimaging and the advent of relevant animal models allowing the identification of the pathophysiological pathways leading to CAs. The rationale behind treatments is now established for most of the CAs encountered during daily practice worldwide. In this update, we will discuss the symptomatic, physical and occupational therapies now being trialled along with individualized exercises, and present key emerging issues on immune-mediated cerebellar ataxias, hereditary cerebellar ataxias. Finally, we will discuss novel therapeutic approaches, including cerebellar non-invasive stimulation and treatments acting on RNA/proteins. So far, no state-of-the art randomized placebo-controlled clinical trial has shown a convincing clinically relevant efficacy of any drug, with the exception of 4-aminopyridine for the symptomatic treatment of episodic ataxia type 2 and downbeat nystagmus (placebo-controlled trials).

Kuo SH (2019) Ataxia. Continuum (Minneap Minn) 25(4):1036–1054

Manto M, Gandini J, Feil K, Strupp M (2020) Cerebellar ataxias: an update. Curr Opin Neurol 33(1):150–160CrossRefPubMed

Bürk K, Sival DA (2018) Scales for the clinical evaluation of cerebellar disorders. Handb Clin Neurol 154:329–339CrossRefPubMed

Perlman S, Boltshauser E (2018) Drug treatment. Handb Clin Neurol 155:371–377CrossRefPubMed

Schatton C, Synofzik M, Fleszar Z, Giese MA, Schöls L, Ilg W (2017) Individualized exergame training improves postural control in advanced degenerative spinocerebellar ataxia: a rater-blinded, intra-individually controlled trial. Parkinsonism Relat Disord 39:80–84CrossRefPubMed

Mitoma H, Manto M, Hampe CS (2017) Immune-mediated cerebellar ataxias: from bench to bedside. Cerebellum Ataxias 4:16CrossRefPubMedPubMedCentral

Joubert B, Rostásy K, Honnorat J (2018) Immune-mediated ataxias. Handb Clin Neurol 155:313–332CrossRefPubMed

Mitoma H, Manto M, Hampe CS (2019) Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges. Curr Neuropharmacol 17(1):33–58CrossRefPubMedPubMedCentral

Beaudin M, Matilla-Dueñas A, Soong BW, Pedroso JL, Barsottini OG, Mitoma H, Tsuji S, Schmahmann JD, Manto M, Rouleau GA, Klein C, Dupre N (2019) The classification of autosomal recessive cerebellar ataxias: a consensus statement from the society for research on the cerebellum and ataxias task force. Cerebellum. https://doi.org/10.1007/s12311-019-01052-2 CrossRefPubMedPubMedCentral

10.

Synofzik M, Puccio H, Mochel F, Schöls L (2019) Autosomal recessive cerebellar ataxias: paving the way toward targeted molecular therapies. Neuron 101(4):560–583CrossRefPubMed

11.

Gottesfeld JM (2019) Molecular mechanisms and therapeutics for the GAA·TTC expansion disease Friedreich ataxia. Neurotherapeutics. https://doi.org/10.1007/s13311-019-00764-x CrossRefPubMedPubMedCentral

12.

Cook A, Boesch S, Heck S, Brunt E, Klockgether T, Schöls L, Schulz A, Giunti P (2019) Patient-reported outcomes in Friedreich’s ataxia after withdrawal from idebenone. Acta Neurol Scand 139(6):533–539CrossRefPubMed

13.

Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, Spino M, Tricta F (2014) Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol 76(4):509–521CrossRefPubMed

14.

Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, Poewe W (2008) Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord 23(13):1940–1944CrossRefPubMed

15.

Lynch DR, Hauser L, McCormick A et al (2019) Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich ataxia. Ann Clin Transl Neurol 6(3):546–553CrossRefPubMedPubMedCentral

16.

Lynch DR, Schadt K, Kichula E (2019) Etravirine in Friedreich’s ataxia: lessons from HIV? Mov Disord 34(3):305–306CrossRefPubMed

17.

Barca E, Emmanuele V, DiMauro S, Toscano A, Quinzii CM (2019) Anti-oxidant drugs: novelties and clinical implications in cerebellar ataxias. Curr Neuropharmacol 17(1):21–32CrossRefPubMedPubMedCentral

18.

Salviati L, Trevisson E, Doimo M, Navas P (eds) (2017) Primary coenzyme Q10 deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, Stephens K, Amemiya A, Ledbetter N (eds) GeneReviews® [Internet]. University of Washington, Seattle, pp 1993–2017

19.

Fiorucci S, Distrutti E (2019) Chenodeoxycholic acid: an update on its therapeutic applications. Handb Exp Pharmacol. https://doi.org/10.1007/164_2019_226 CrossRefPubMed

20.

Mohr I, Weiss KH (2019) Biochemical markers for the diagnosis and monitoring of wilson disease. Clin Biochem Rev 40(2):59–77CrossRefPubMedPubMedCentral

21.

Zannolli R, Buoni S, Betti G, Salvucci S, Plebani A, Soresina A, Pietrogrande MC, Martino S, Leuzzi V, Finocchi A, Micheli R, Rossi LN, Brusco A, Misiani F, Fois A, Hayek J, Kelly C, Chessa L (2012) A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 27(10):1312–1316CrossRefPubMed

22.

Pineda M, Juríčková K, Karimzadeh P, Kolnikova M, Malinova V, Insua JL, Velten C, Kolb SA (2019) Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis 14(1):32CrossRefPubMedPubMedCentral

23.

Bremova T, Malinová V, Amraoui Y, Mengel E, Reinke J, Kolníková M, Strupp M (2015) Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology 85(16):1368–1375CrossRefPubMed

24.

Vibert N, Vidal PP (2001) In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 13:735–748CrossRefPubMed

25.

Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, Fukuda C, Kubota N, Takayama R, Shigematsu H, Hayashi A, Kumada T, Yuge K, Watanabe Y, Kosugi S, Nishida H, Kimura Y, Endo Y, Higaki K, Nanba E, Nishimura Y, Tamasaki A, Togawa M, Saito Y, Maegaki Y, Ohno K, Suzuki Y (2016) Ambroxol chaperone therapy for neuronopathic gaucher disease: a pilot study. Ann Clin Transl Neurol 3(3):200–215CrossRefPubMedPubMedCentral

26.

Wolf B (2017) Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening. Genet Med 19(4):396–402CrossRefPubMed

27.

Szmulewicz DJ, McLean CA, Rodriguez ML, Chancellor AM, Mossman S, Lamont D, Roberts L, Storey E, Halmagyi GM (2014) Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS. Neurology 82(16):1410–1415CrossRefPubMedPubMedCentral

28.

Szmulewicz DJ, Roberts L, McLean CA, MacDougall HG, Halmagyi GM, Storey E (2016) Proposed diagnostic criteria for cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS). Neurol Clin Pract 6(1):61–68CrossRefPubMedPubMedCentral

29.

Moreno-Ajona D, Álvarez-Gómez L, Manrique-Huarte R, Rivas E, Martínez-Vila E, Pérez-Fernández N (2019) VEMPs and dysautonomia assessment in definite cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS): a case series study. Cerebellum. https://doi.org/10.1007/s12311-019-01061-1 CrossRef

30.

Cortese A, Simone R, Sullivan R, Vandrovcova J, Tariq H, Yau WY, Humphrey J, Jaunmuktane Z, Sivakumar P, Polke J, Ilyas M, Tribollet E, Tomaselli PJ, Devigili G, Callegari I, Versino M, Salpietro V, Efthymiou S, Kaski D, Wood NW, Andrade NS, Buglo E, Rebelo A, Rossor AM, Bronstein A, Fratta P, Marques WJ, Züchner S, Reilly MM, Houlden H (2019) Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet 51(4):649–658CrossRefPubMedPubMedCentral

31.

Rafehi H, Szmulewicz DJ, Bennett MF, Sobreira NLM, Pope K, Smith KR, Gillies G, Diakumis P, Dolzhenko E, Eberle MA, Barcina MG, Breen DP, Chancellor AM, Cremer PD, Delatycki MB, Fogel BL, Hackett A, Halmagyi GM, Kapetanovic S, Lang A, Mossman S, Mu W, Patrikios P, Perlman SL, Rosemergy I, Storey E, Watson SRD, Wilson MA, Zee DS, Valle D, Amor DJ, Bahlo M, Lockhart PJ (2019) Bioinformatics-based identification of expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS. Am J Hum Genet 105(1):151–165CrossRefPubMedPubMedCentral

32.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP et al (2018) Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 90(10):464–471CrossRefPubMedPubMedCentral

33.

Manes M, Alberici A, Di Gregorio E et al (2017) Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38. Ann Neurol 82(4):615–621CrossRefPubMedPubMedCentral

34.

Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández-Gálvez M, Fernández-Ruiz J (2019) Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: potential role in pathogenesis and expected relevance as neuroprotective targets. Front Mol Neurosci 12:94CrossRefPubMedPubMedCentral

35.

Griggs RC, Moxley RT 3rd, Lafrance RA, McQuillen J (1978) Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 28(12):1259–1264CrossRefPubMed

36.

Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62(9):1623–1625CrossRefPubMed

37.

Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77(3):269–275CrossRefPubMedPubMedCentral

38.

Strupp M, Teufel J, Zwergal A, Schniepp R, Khodakhah K, Feil K (2017) Aminopyridines for the treatment of neurologic disorders. Neurol Clin Pract 7(1):65–76CrossRefPubMedPubMedCentral

39.

Etzion Y, Grossman Y (2001) Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res 139:419–425CrossRefPubMed

40.

Alvina K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 30:7258–7268CrossRefPubMedPubMedCentral

41.

Hourez R, Servais L, Orduz D et al (2011) Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 31:11795–11807CrossRefPubMedPubMedCentral

42.

Strupp M, Zwergal A, Brandt T (2007) Episodic ataxia type 2. Neurotherapeutics 4:267–273CrossRefPubMed

43.

Wagner JN, Glaser M, Brandt T, Strupp M (2008) Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry 79:672–677CrossRefPubMed

44.

Kalla R, Deutschlander A, Hufner K et al (2006) Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology 66:281–283CrossRefPubMed

45.

Strupp M, Schüler O, Krafczyk S, Jahn K, Schautzer F, Büttner U, Brandt T (2003) Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 61(2):165–170CrossRefPubMed

46.

Claassen J, Spiegel R, Kalla R et al (2013) A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus–effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 84:1392–1399CrossRefPubMed

47.

Ilg W, Bastian AJ, Boesch S et al (2014) Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13:248–268CrossRefPubMedPubMedCentral

48.

Claassen J, Feil K, Bardins S et al (2013) Dalfampridine in patients with downbeat nystagmus: an observational study. J Neurol 260:1992–1996CrossRefPubMed

49.

Schniepp R, Wuehr M, Neuhaeusser M, Benecke AK, Adrion C, Brandt T, Strupp M, Jahn K (2012) 4-aminopyridine and cerebellar gait: a retrospective case series. J Neurol 259:2491–2493CrossRefPubMed

50.

Giordano I, Bogdanow M, Jacobi H, Jahn K, Minnerop M, Schoels L et al (2013) Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J Neurol 260:2175–2176CrossRefPubMed

51.

van Dun K, Bodranghien F, Manto M, Mariën P (2014) Targeting the cerebellum by noninvasive neurostimulation: a review. Cerebellum 16(3):695–741CrossRef

52.

Oldrati V, Schutter D (2018) Targeting the human cerebellum with transcranial direct current stimulation to modulate behavior: a meta-analysis. Cerebellum 17(2):228–236CrossRefPubMed

53.

Bodranghien F, Oulad Ben Taib N, Van Maldergem L, Manto M (2017) A postural tremor highly responsive to transcranial cerebello-cerebral DCS in ARCA3. Front Neurol 8:71CrossRefPubMedPubMedCentral

54.

Benussi A, Koch G, Cotelli M, Padovani A, Borroni B (2015) Cerebellar transcranial direct current stimulation in patients with ataxia: a double-blind, randomized, sham-controlled study. Mov Disord 30(12):1701–1705CrossRefPubMed

55.

Benussi A, Dell'Era V, Cotelli MS, Turla M, Casali C, Padovani A, Borroni B (2017) Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia. Brain Stimul 10(2):242–250CrossRefPubMed

56.

Benussi A, Dell'Era V, Cantoni V, Bonetta E, Grasso R, Manenti R, Cotelli M, Padovani A, Borroni B (2018) Cerebello-spinal tDCS in ataxia: a randomized, double-blind, sham-controlled, crossover trial. Neurology 91(12):e1090–e1101CrossRefPubMed

57.

Klockgether T, Mariotti C, Paulson HL (2019) Spinocerebellar ataxia. Nat Rev Dis Primers 5(1):24CrossRefPubMed

58.

Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM (2017) Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544(7650):362–366CrossRefPubMedPubMedCentral

59.

Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, Hung G, Kordasiewicz HB, Paulson HL, McLoughlin HS (2017) Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models. Mol Ther Nucleic Acids 7:200–210CrossRefPubMedPubMedCentral

60.

McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, Zhao H, Kordasiewicz HB, Shakkottai VG, Paulson HL (2018) Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol 84(1):64–77CrossRefPubMedPubMedCentral

61.

Pérez Ortiz JM, Orr HT (2018) Spinocerebellar ataxia type 1: molecular mechanisms of neurodegeneration and preclinical studies. Adv Exp Med Biol 1049:135–145CrossRefPubMed

62.

Cendelin J, Buffo A, Hirai H, Magrassi L, Mitoma H, Sherrard R, Vozeh F, Manto M (2019) Task force paper on cerebellar transplantation: are we ready to treat cerebellar disorders with cell therapy? Cerebellum 18(3):575–592CrossRefPubMed

63.

Piguet F, de Montigny C, Vaucamps N, Reutenauer L, Eisenmann A, Puccio H (2018) Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol Ther 26(8):1940–1952CrossRefPubMedPubMedCentral

64.

Gérard C, Xiao X, Filali M, Coulombe Z, Arsenault M, Couet J, Li J, Drolet MC, Chapdelaine P, Chikh A, Tremblay JP (2014) An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models. Mol Ther Methods Clin Dev 1:14044CrossRefPubMedPubMedCentral

65.

Nayler S, Kozlov SV, Lavin MF, Wolvetang E (2017) Lentiviral reprogramming of A-T patient fibroblasts to induced pluripotent stem cells. Methods Mol Biol 1599:401–418CrossRefPubMed

66.

Carranza D, Torres-Rusillo S, Ceballos-Pérez G, Blanco-Jimenez E, Muñoz-López M, García-Pérez JL, Molina IJ (2018) Reconstitution of the ataxia-telangiectasia cellular phenotype with lentiviral vectors. Front Immunol 9:2703CrossRefPubMedPubMedCentral

67.

Dezawa M, Ishikawa H, Hoshino M, Itokazu Y, Nabeshima Y (2005) Potential of bone marrow stromal cells in applications for neuro-degenerative, neuro-traumatic and muscle degenerative diseases. Curr Neuropharmacol 3(4):257–266CrossRefPubMedPubMedCentral

68.

Hayashi T, Onoe H (2013) Neuroimaging for optimization of stem cell therapy in Parkinson’s disease. Expert Opin Biol Ther 13(12):1631–1638CrossRefPubMed

69.

Choumerianou DM, Dimitriou H, Kalmanti M (2008) Stem cells: promises versus limitations. Tissue Eng Part B Rev 14(1):53–60CrossRefPubMed

70.

Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, Cheong JW, Jeong Y, Park HJ, Kim DJ, Nam CM, Lee JD, Kim HO, Sohn YH (2012) A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 72(1):32–40CrossRefPubMed

71.

Matsuura S, Shuvaev AN, Iizuka A, Nakamura K, Hirai H (2014) Mesenchymal stem cells ameliorate cerebellar pathology in a mouse model of spinocerebellar ataxia type 1. Cerebellum 13(3):323–330CrossRefPubMed

72.

Oliveira Miranda C, Marcelo A, Silva TP, Barata J, Vasconcelos-Ferreira A, Pereira D, Nóbrega C, Duarte S, Barros I, Alves J, Sereno J, Petrella LI, Castelhano J, Paiva VH, Rodrigues-Santos P, Alves V, Nunes-Correia I, Nobre RJ, Gomes C, Castelo-Branco M, Pereira de Almeida L (2018) Repeated mesenchymal stromal cell treatment sustainably alleviates machado-joseph disease. Mol Ther 26(9):2131–2151CrossRefPubMedPubMedCentral

Titel: The neurological update: therapies for cerebellar ataxias in 2020
verfasst von: J. Gandini
Mario Manto
T. Bremova-Ertl
K. Feil
M. Strupp
Publikationsdatum: 30.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 4/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09717-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The neurological update: therapies for cerebellar ataxias in 2020

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Systematic review of the clinical spectrum of CASPR2 antibody syndrome

A systematic review on the definition of rhabdomyolysis

Premature vascular disease in young adult stroke: a pathology-based case series

Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange

Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study

Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie